| pubmed-article:9576583 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9576583 | lifeskim:mentions | umls-concept:C0332437 | lld:lifeskim |
| pubmed-article:9576583 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:9576583 | lifeskim:mentions | umls-concept:C0005953 | lld:lifeskim |
| pubmed-article:9576583 | lifeskim:mentions | umls-concept:C0370003 | lld:lifeskim |
| pubmed-article:9576583 | lifeskim:mentions | umls-concept:C0079611 | lld:lifeskim |
| pubmed-article:9576583 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:9576583 | lifeskim:mentions | umls-concept:C0806140 | lld:lifeskim |
| pubmed-article:9576583 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:9576583 | pubmed:dateCreated | 1998-5-14 | lld:pubmed |
| pubmed-article:9576583 | pubmed:abstractText | For this study, 188 bone marrow core biopsy specimens and aspirates analyzed morphologically and by flow cytometric immunophenotyping (FCI) in patients with a previous or new diagnosis of B-cell non-Hodgkin's lymphoma or mature B-cell leukemia were retrospectively reviewed to evaluate patterns of involvement and the usefulness of FCI. The morphologic and FCI results were categorized as follows: positive by morphologic examination and by FCI (39.9%); negative by morphologic examination and by FCI (41.5%); positive by morphologic examination and negative by FCI (11.7%); negative by morphologic examination and positive by FCI (2.6%); suggestive of malignant neoplasm by morphologic examination and positive by FCI (2.1%); and suggestive of malignant neoplasm by morphologic examination and negative by FCI (2.1%). Thus, in 81.4% of cases the morphologic and FCI findings were completely concordant. In 11.7% of cases, the morphologic examination alone detected involvement, and in 4.7% of cases, the FCI data detected involvement in a morphologically negative or "suggestive" bone marrow core. Combining these modalities is essential to evaluate bone marrow specimens for involvement by B-cell non-Hodgkin's lymphoma or B-cell leukemia. | lld:pubmed |
| pubmed-article:9576583 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9576583 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9576583 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9576583 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9576583 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9576583 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9576583 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9576583 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9576583 | pubmed:month | May | lld:pubmed |
| pubmed-article:9576583 | pubmed:issn | 0002-9173 | lld:pubmed |
| pubmed-article:9576583 | pubmed:author | pubmed-author:DunphyC HCH | lld:pubmed |
| pubmed-article:9576583 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9576583 | pubmed:volume | 109 | lld:pubmed |
| pubmed-article:9576583 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9576583 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9576583 | pubmed:pagination | 625-30 | lld:pubmed |
| pubmed-article:9576583 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:9576583 | pubmed:meshHeading | pubmed-meshheading:9576583-... | lld:pubmed |
| pubmed-article:9576583 | pubmed:meshHeading | pubmed-meshheading:9576583-... | lld:pubmed |
| pubmed-article:9576583 | pubmed:meshHeading | pubmed-meshheading:9576583-... | lld:pubmed |
| pubmed-article:9576583 | pubmed:meshHeading | pubmed-meshheading:9576583-... | lld:pubmed |
| pubmed-article:9576583 | pubmed:meshHeading | pubmed-meshheading:9576583-... | lld:pubmed |
| pubmed-article:9576583 | pubmed:meshHeading | pubmed-meshheading:9576583-... | lld:pubmed |
| pubmed-article:9576583 | pubmed:meshHeading | pubmed-meshheading:9576583-... | lld:pubmed |
| pubmed-article:9576583 | pubmed:meshHeading | pubmed-meshheading:9576583-... | lld:pubmed |
| pubmed-article:9576583 | pubmed:meshHeading | pubmed-meshheading:9576583-... | lld:pubmed |
| pubmed-article:9576583 | pubmed:meshHeading | pubmed-meshheading:9576583-... | lld:pubmed |
| pubmed-article:9576583 | pubmed:meshHeading | pubmed-meshheading:9576583-... | lld:pubmed |
| pubmed-article:9576583 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9576583 | pubmed:articleTitle | Combining morphology and flow cytometric immunophenotyping to evaluate bone marrow specimens for B-cell malignant neoplasms. | lld:pubmed |
| pubmed-article:9576583 | pubmed:affiliation | Department of Pathology, St Louis University Health Sciences Center, Missouri 63104, USA. | lld:pubmed |
| pubmed-article:9576583 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9576583 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9576583 | lld:pubmed |
